Physician
Shearer, Robert
Shearer, Robert was paid $1.02M by Medicaid between Jan 2018 and Dec 2020, across 20 billing codes. Its largest line is H0016, Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) — 42% of everything it billed.
33Billing provider infoSHEARER, ROBERT
SPRINGFIELD, TN 37172
SPRINGFIELD, TN 37172
33aNPI1134142987assigned 07/25/2006
33bProvider typeGynecology Physician
28Total paid$1.02M
24GClaims21,687
24DCodes billed20
24AFirst – last monthJan 2018 – Dec 2020
Compared with peers
Next to other Gynecology Physician providers in Tennessee
Rank by total paid#1 of 15
Median peer was paid$12K
This provider vs. median83×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,989 | $365K | |
| 2019 | 6,589 | $371K | |
| 2020 | 4,109 | $281K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 42% | 2,349 | 1,392 | $426K |
| H2010 | Comprehensive medication services, per 15 minutes | 16% | 3,252 | 1,172 | $164K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 3,608 | 1,545 | $137K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.7% | 2,503 | 982 | $89K |
| H0033 | Oral medication administration, direct observation | 5.1% | 582 | 253 | $52K |
| 99484 | 3.9% | 1,288 | 1,185 | $40K | |
| 80305 | 3.8% | 6,992 | 2,869 | $39K | |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | 3.1% | 188 | 125 | $31K |
| 99205 | Prolong outpt/office vis | 1.1% | 188 | 85 | $12K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 91 | 82 | $7K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 134 | 98 | $6K |
| 99492 | <1% | 38 | 38 | $4K |
8 more codes
| 99203 | Doctor's office visit, new patient (routine) | <1% | 59 | $4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 107 | $3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 85 | $3K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 19 | $263.37 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 19 | $263.15 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 137 | $125.88 |
| 81025 | <1% | 18 | $52.93 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 30 | $21.21 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.